{"id":792642,"date":"2026-02-25T22:26:01","date_gmt":"2026-02-25T22:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=792642"},"modified":"2026-02-25T22:26:01","modified_gmt":"2026-02-25T22:26:01","slug":"rinvoq-market-growth-accelerates-across-ibd-dermatology-and-rheumatology-as-global-sales-momentum-strengthens-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rinvoq-market-growth-accelerates-across-ibd-dermatology-and-rheumatology-as-global-sales-momentum-strengthens-delveinsight_792642.html","title":{"rendered":"RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Global Sales Momentum Strengthens | DelveInsight"},"content":{"rendered":"
\n
\"RINVOQ<\/a><\/div>\n
\n
RINVOQ Market<\/div>\n<\/div>\n<\/div>\n
The global immunology market is witnessing a significant transformation as RINVOQ (upadacitinib) continues to demonstrate strong prescription growth, expanding indications, and robust revenue performance.<\/div>\n

DelveInsight’s “RINVOQ Sales Forecast, and Market Size Analysis – 2034”<\/strong> report provides comprehensive insights of RINVOQ for approved indications like Ankylosing Spondylitis, Atopic Dermatitis, Axial SpA, Crohn’s Disease, Giant Cell Arteritis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis; as well as potential indications like Alopecia Areata, Hidradenitis Suppurativa, Systemic Lupus Erythematosus (SLE), Takayasu Arteritis, and Vitiligo in the 7MM.<\/p>\n

According to insights by DelveInsight, RINVOQ is rapidly emerging as a leading oral JAK inhibitor across multiple autoimmune and inflammatory diseases, positioning itself as a key growth driver in AbbVie’s immunology portfolio.<\/p>\n

 <\/p>\n

Download the Complete RINVOQ Sales Forecast Report (2020–2034) to<\/em> access detailed revenue projections, peak sales estimates, and competitive intelligence across the 7MM @ <\/strong>RINVOQ Market Forecast<\/strong><\/a><\/p>\n

 <\/p>\n

Key Factors Driving RINVOQ Market Growth<\/strong><\/p>\n

1. Rising Market Share and Surge in New Patient Starts<\/strong><\/p>\n

RINVOQ is steadily gaining market share across major autoimmune disease segments, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn’s disease<\/strong>.<\/p>\n

A marked increase in new patient starts has fueled prescription growth, supported by strong physician confidence and strategic commercial initiatives led by AbbVie. Focused physician education programs and expanded market access strategies are further strengthening adoption rates across the United States, Europe, and Japan.<\/p>\n

 <\/p>\n

2. Expansion Across Key Indications<\/strong><\/p>\n

Inflammatory Bowel Disease (IBD):<\/strong> RINVOQ is gaining substantial traction in ulcerative colitis and Crohn’s disease<\/strong>, backed by favorable clinical trial data and growing real-world evidence (RWE). IBD continues to be a primary revenue contributor, with strong volume momentum observed across major markets.<\/p>\n

Atopic Dermatitis:<\/strong> In the moderate-to-severe atopic dermatitis segment, RINVOQ has emerged as one of the leading oral treatment options, offering convenience over injectable biologics and driving improved patient adherence.<\/p>\n

Spondyloarthritis and Psoriatic Arthritis:<\/strong> The therapy is increasingly preferred in axial spondyloarthritis and psoriatic arthritis due to its oral small-molecule profile and competitive efficacy outcomes, providing an attractive alternative to TNF inhibitors and other biologics.<\/p>\n

Pipeline developments further indicate potential label expansions in alopecia areata, hidradenitis suppurativa, systemic lupus erythematosus (SLE), Takayasu arteritis, and vitiligo<\/strong>, which are expected to broaden the RINVOQ market size through 2034.<\/p>\n

 <\/p>\n

3. Geographic Expansion Driving Global Uptake<\/strong><\/p>\n

RINVOQ continues to expand into both developed and emerging markets. The Asia-Pacific region<\/strong> is projected to experience the fastest growth, driven by rising autoimmune disease prevalence, expanding healthcare infrastructure, and improved awareness of advanced targeted therapies.<\/p>\n

AbbVie’s strengthened local partnerships and distribution networks are accelerating RINVOQ uptake across Europe and Japan, reinforcing its global commercial footprint.<\/p>\n

 <\/p>\n

4. New Indication Approvals Enhancing Competitive Position<\/strong><\/p>\n

Regulatory approvals are significantly expanding RINVOQ’s treatment landscape.<\/p>\n

In April 2025, the European Commission<\/strong> granted marketing authorization to RINVOQ (15 mg once daily) for the treatment of giant cell arteritis (GCA)<\/strong> in adult patients, making it the first and only oral JAK inhibitor approved in the EU for this condition.<\/p>\n

In the United States, RINVOQ is approved for pediatric patients aged two years and older with polyarticular juvenile idiopathic arthritis (pJIA)<\/strong> and psoriatic arthritis (PsA)<\/strong> who have had inadequate responses to TNF blockers. The launch of a weight-based oral solution, RINVOQ LQ<\/strong>, further expands its pediatric rheumatology portfolio.<\/p>\n

 <\/p>\n

5. Strong IBD Volume Momentum<\/strong><\/p>\n

IBD remains a cornerstone growth segment for RINVOQ. Updated 2025 insights highlight sustained prescription gains in ulcerative colitis and Crohn’s disease markets, driven by superior efficacy data and increasing reliance on real-world evidence.<\/p>\n

Growing payer confidence, combined with value-based care models, is further supporting long-term market penetration.<\/p>\n

 <\/p>\n

Request a Free Sample Copy of the RINVOQ Market Analysis and explore in-depth insights on pricing trends, regulatory milestones, and pipeline expansion. @ RINVOQ Sales and Cost Analysis<\/a><\/strong><\/p>\n

 <\/p>\n

Recent RINVOQ Developments Strengthening Market Position<\/strong><\/p>\n

In July 2025, AbbVie announced positive topline results from the Phase III UP-AA program evaluating RINVOQ (15 mg and 30 mg once daily) in patients with severe alopecia areata. The study demonstrated promising efficacy in a population with significant scalp hair loss.<\/p>\n

RINVOQ is currently in Phase III clinical development for multiple high-value indications, including:<\/p>\n